Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Cadonilimab for Recurrent Small Cell Neuroendocrine Cervical Cancer
NCT05063916Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in neuroendocrine carcinoma of the cervix (NECC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival Rate at 6 Months. Started Feb 2022; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
neuroendocrine carcinoma of the cervix (NECC)
Beyond the preview
Go deeper on NCT05063916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063916.